מזומני החברה: Cardio Diagnostics Holdings, Inc. (CDIO)

Cardio Diagnostics operates advanced US laboratories where AI and genetics diagnose cardiac pathologies. Cash reserves show a turning point driven by the implementation of a unique epigenetic test for the early detection of ischemia. Business resilience is bolstered by outsourcing biosample logistics to partners while maintaining control over the software. The value of 0.00 shows the latest value of this liquidity metric.
פילוחים אנליטיים של חברת Cardio Diagnostics

The volume of liquid assets determines the issuer's actual solvency and protects against cash flow gaps. This metric measures available cash reserves, excluding accounting distortions to assess the quality of reserves. By analyzing the magnitude of cash accumulations, an investor can see the resources available for the diversification of Cardio Diagnostics (CDIO). This is critical during the transition to a subscription model and integration with insurance companies. The stability of this indicator confirms the financial resilience of the AI platform development strategy.